{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T19:18:44Z","timestamp":1726514324387},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T00:00:00Z","timestamp":1483660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.vaccine.2016.12.060","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T21:09:58Z","timestamp":1483736998000},"page":"929-937","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies"],"prefix":"10.1016","volume":"35","author":[{"given":"Gerald K.","family":"Chege","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey L.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive M.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enid G.","family":"Shephard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan W.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Lise","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2016.12.060_b0005","first-page":"326","article-title":"Progress in HIV-1 vaccine development","volume":"8","author":"Haynes","year":"2013","journal-title":"Curr Opin HIV and AIDS"},{"issue":"4","key":"10.1016\/j.vaccine.2016.12.060_b0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ni.2844","article-title":"Vaccines that stimulate T cell immunity to HIV-1: the next step","volume":"15","author":"McMichael","year":"2014","journal-title":"Nat Immunol"},{"issue":"7037","key":"10.1016\/j.vaccine.2016.12.060_b0015","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nature03513","article-title":"Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells","volume":"434","author":"Li","year":"2005","journal-title":"Nature"},{"issue":"7037","key":"10.1016\/j.vaccine.2016.12.060_b0020","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/nature03501","article-title":"Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection","volume":"434","author":"Mattapallil","year":"2005","journal-title":"Nature"},{"issue":"5362","key":"10.1016\/j.vaccine.2016.12.060_b0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1126\/science.280.5362.427","article-title":"Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection","volume":"280","author":"Veazey","year":"1998","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.vaccine.2016.12.060_b0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ni1316","article-title":"HIV disease: fallout from a mucosal catastrophe?","volume":"7","author":"Brenchley","year":"2006","journal-title":"Nat Immunol"},{"issue":"7348","key":"10.1016\/j.vaccine.2016.12.060_b0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"issue":"7469","key":"10.1016\/j.vaccine.2016.12.060_b0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2016.12.060_b0045","doi-asserted-by":"crossref","first-page":"D4","DOI":"10.1016\/j.vaccine.2015.03.059","article-title":"Prospects for a globally effective HIV-1 vaccine","volume":"33","author":"Excler","year":"2015","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2016.12.060_b0050","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1128\/CVI.00230-14","article-title":"Nonneutralizing functional antibodies: a new \u201cold\u201d paradigm for HIV vaccines","volume":"21","author":"Excler","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"23","key":"10.1016\/j.vaccine.2016.12.060_b0055","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2016.12.060_b0060","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jis367","article-title":"Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials","volume":"206","author":"Montefiori","year":"2012","journal-title":"J Infect Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2016.12.060_b0065","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.12.060_b0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-med-052912-123749","article-title":"Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection","volume":"66","author":"Kim","year":"2015","journal-title":"Annu Rev Med"},{"issue":"228","key":"10.1016\/j.vaccine.2016.12.060_b0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1\u2013V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"Yates","year":"2014","journal-title":"Sci Transl Med"},{"issue":"21","key":"10.1016\/j.vaccine.2016.12.060_b0080","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J Virol"},{"issue":"7383","key":"10.1016\/j.vaccine.2016.12.060_b0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys","volume":"482","author":"Barouch","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2016.12.060_b0090","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"issue":"81","key":"10.1016\/j.vaccine.2016.12.060_b0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002351","article-title":"Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys","volume":"3","author":"Letvin","year":"2011","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.vaccine.2016.12.060_b0100","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1128\/JVI.02544-12","article-title":"Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial","volume":"87","author":"Pegu","year":"2013","journal-title":"J Virol"},{"issue":"14","key":"10.1016\/j.vaccine.2016.12.060_b0105","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1128\/JVI.00156-14","article-title":"HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities","volume":"88","author":"Pollara","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.12.060_b0110","doi-asserted-by":"crossref","unstructured":"de Taeye SW. HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies; 2016.","DOI":"10.1016\/j.it.2016.01.007"},{"key":"10.1016\/j.vaccine.2016.12.060_b0115","unstructured":"Yamamoto T. Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection; 2015."},{"issue":"2","key":"10.1016\/j.vaccine.2016.12.060_b0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3054","article-title":"Harnessing CD4(+) T cell responses in HIV vaccine development","volume":"19","author":"Streeck","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2016.12.060_b0125","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/QAD.0b013e328342ff93","article-title":"Global trends in molecular epidemiology of HIV-1 during 2000\u20132007","volume":"25","author":"Hemelaar","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2016.12.060_b0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1099\/vir.0.81379-0","article-title":"Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial","volume":"87","author":"Burgers","year":"2006","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.12.060_b0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/aid.2007.0205","article-title":"Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C","volume":"24","author":"Burgers","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"10.1016\/j.vaccine.2016.12.060_b0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/aid.2007.0206","article-title":"A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice","volume":"24","author":"Shephard","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"10.1016\/j.vaccine.2016.12.060_b0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7196\/SAMJ.5668","article-title":"South African HIV-1 vaccine candidates - the journey from the bench to clinical trials","volume":"102","author":"Williamson","year":"2012","journal-title":"S Afr Med J"},{"issue":"21","key":"10.1016\/j.vaccine.2016.12.060_b0150","doi-asserted-by":"crossref","first-page":"13338","DOI":"10.1128\/JVI.79.21.13338-13349.2005","article-title":"Evaluation of envelope Vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain","volume":"79","author":"Lian","year":"2005","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.12.060_b0155","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.1402604","article-title":"Oil-in-water emulsion MF59 increases germinal center B cell differentiation and persistence in response to vaccination","volume":"195","author":"Lofano","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.12.060_b0160","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1099\/vir.0.004614-0","article-title":"Broad, high-magnitude and multifunctional CD4(+) and CD8(+) T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons","volume":"90","author":"Burgers","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.12.060_b0165","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1099\/vir.0.83501-0","article-title":"HIV-1 subtype CPr55(gag) virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine","volume":"89","author":"Chege","year":"2008","journal-title":"J Gen Virol"},{"issue":"35","key":"10.1016\/j.vaccine.2016.12.060_b0170","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1016\/j.vaccine.2009.05.064","article-title":"A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons","volume":"27","author":"Chege","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.060_b0175","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"issue":"8","key":"10.1016\/j.vaccine.2016.12.060_b0180","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cyto.a.21084","article-title":"High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses","volume":"79A","author":"Pollara","year":"2011","journal-title":"Cytometry Part A"},{"issue":"24","key":"10.1016\/j.vaccine.2016.12.060_b0185","doi-asserted-by":"crossref","first-page":"13904","DOI":"10.1128\/JVI.01401-07","article-title":"Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study","volume":"81","author":"Potter","year":"2007","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2016.12.060_b0190","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.4049\/jimmunol.0803801","article-title":"Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point","volume":"182","author":"Burgers","year":"2009","journal-title":"J Immunol"},{"issue":"14","key":"10.1016\/j.vaccine.2016.12.060_b0195","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1128\/JVI.79.14.9217-9227.2005","article-title":"Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus","volume":"79","author":"Miller","year":"2005","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2016.12.060_b0200","doi-asserted-by":"crossref","first-page":"e19493","DOI":"10.1371\/journal.pone.0019493","article-title":"Rapid dissemination of SIV follows multisite entry after rectal inoculation","volume":"6","author":"Ribeiro Dos","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.060_b0205","doi-asserted-by":"crossref","unstructured":"Gray GE. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap; 2016.","DOI":"10.1128\/CVI.00717-15"},{"issue":"1","key":"10.1016\/j.vaccine.2016.12.060_b0210","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1128\/JVI.02523-13","article-title":"Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques","volume":"88","author":"Manrique","year":"2014","journal-title":"J Virol"},{"issue":"16","key":"10.1016\/j.vaccine.2016.12.060_b0215","doi-asserted-by":"crossref","first-page":"8672","DOI":"10.1128\/JVI.00287-12","article-title":"Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding","volume":"86","author":"Smalls-Mantey","year":"2012","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.12.060_b0220","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.4049\/jimmunol.174.4.2185","article-title":"Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251","volume":"174","author":"Gomez-Roman","year":"2005","journal-title":"J Immunol"},{"issue":"22","key":"10.1016\/j.vaccine.2016.12.060_b0225","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"10.1016\/j.vaccine.2016.12.060_b0230","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/QAD.0000000000000310","article-title":"Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design","volume":"28","author":"Madhavi","year":"2014","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.vaccine.2016.12.060_b0235","doi-asserted-by":"crossref","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.12.060_b0240","doi-asserted-by":"crossref","unstructured":"Moldt B. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo; 2012.","DOI":"10.1073\/pnas.1214785109"},{"issue":"3","key":"10.1016\/j.vaccine.2016.12.060_b0245","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2016.12.060_b0250","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.immuni.2013.08.031","article-title":"Human circulating PD-1(+)CXCR3(-)CXCR5(+) memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses","volume":"39","author":"Locci","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2016.12.060_b0255","unstructured":"HIV Research for Protection 2016. Abstract book (Oral posters OA22.03 & OA22.04). Aids Research and Human Retroviruses 32[S1], 100; 2016."},{"issue":"51","key":"10.1016\/j.vaccine.2016.12.060_b0260","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1016\/j.vaccine.2008.09.016","article-title":"Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers","volume":"26","author":"Guimaraes-Walker","year":"2008","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T03:24:10Z","timestamp":1568690650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16312944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0264410X16312944"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}